Lebanese University Faculty of Public Health Entrance Exam study materials
Lebanese University Faculty of Public Health Entrance Exam study resources

Measles in a Displaced-Population Camp: Act Before the Lab

Lebanese University Faculty of Public Health Entrance Exam · Put your knowledge to work in context.

All case studies

Measles in a Displaced-Population Camp: Act Before the Lab

An outbreak of measles is suspected in a camp for displaced families. The camp has 4,000 residents, including 1,200 children aged 9 months to 15 years. Routine records show that 78% of these children have documented one dose of measles-containing vaccine given at 9 months. In the past 3 weeks, 40 children have had fever and rash; 6 have pneumonia and one has died. The camp clinic has no isolation room. The estimated basic reproduction number for measles in this setting is 14. One-dose vaccine effectiveness at 9 months is about 85%. The camp manager proposes to wait for more laboratory results before acting; a donor offers 2,000 doses of measles vaccine and vitamin A. The health team must decide within 48 hours.

1. Calculate the herd immunity threshold and the effective immunity in the camp. Is the observed outbreak consistent with these figures?

Read the worked answer

Herd immunity threshold = 1 − 1/R0 = 1 − 1/14 = 0.929, or about 93%. Effective immunity = coverage × vaccine effectiveness = 0.78 × 0.85 = 0.663, or 66.3%. The gap is about 27 percentage points, and about 34% of children remain susceptible. The effective reproduction number is approximately R0 × susceptible fraction = 14 × 0.337 = 4.7, well above 1. An outbreak is therefore expected, and the observed 40 cases with 6 pneumonia and one death are consistent with a large susceptible pool and crowded camp conditions. The estimate assumes random mixing; in a camp, clustering and crowded shelters can make transmission even more intense. One dose at 9 months is also less effective than two doses, and records may overestimate true coverage.

2. Propose immediate control priorities. Why is waiting for laboratory confirmation risky, and how should the 2,000 vaccine doses and vitamin A be used?

Read the worked answer

Act on the clinical and epidemiological picture now. Measles is highly transmissible and the cost of delay is exponential. Waiting for laboratory results risks missing the window for ring vaccination and outbreak control. Immediate priorities: isolate suspected cases as far as possible, use triage and separate waiting areas, and avoid gathering children in the clinic; notify the health authority; start active case finding; provide vitamin A; manage complications and refer pneumonia; and begin an urgent vaccination campaign.

Use the 2,000 doses for a supplementary campaign targeting children from 6 months to 15 years, with priority to 6–59 months and to areas with the most cases. In outbreak settings, a dose from 6 months is used to protect infants, but it does not replace the routine dose at 9 months; those children still need the routine schedule later. Vitamin A should be given according to age-specific doses, with a second dose the next day for children with signs of vitamin A deficiency or severe measles. The campaign should not wait for all laboratory results, but specimens should still be collected to confirm and monitor.

3. Draft the key messages for families and staff, including how to address vaccine confidence.

Read the worked answer

Families: “Measles spreads very easily through coughs and sneezes. Fever, rash, red eyes and cough may be measles. Bring your child to the clinic early if they have these signs, especially if breathing is fast or the child is drowsy. A free measles vaccine is being offered now to children from 6 months to 15 years. The vaccine is safe and protects most children; a second dose later gives better protection. Keep sick children away from other children where possible.”

Staff: use consistent definitions, record vaccination and symptom dates, isolate suspected cases, and do not turn away children with rash. Address confidence directly: acknowledge that one dose does not guarantee protection and that the camp has many susceptible children; explain that the campaign dose is additional protection, not a sign that earlier vaccination failed. Avoid blaming families. Monitor for adverse events and explain that mild fever or soreness can occur. Give vitamin A and referral information in the same conversation so families leave with a clear action, not only a warning.